SCHEMBL468655

SCHEMBL468655

Nc1nc(Nc2ccc(N3CCN(C4CCCC4)CC3)c(F)c2)n(-c2cc3c(nn2)-c2ccccc2CCC3)n1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 9/20 0.66
KDR P35968 2/20 0.55
EGFR P00533 2/20 0.55
AURKA O14965 1/20 0.55
RET P07949 1/20 0.55
MET P08581 1/20 0.55
KIT P10721 1/20 0.55
SRC P12931 1/20 0.55
PDGFRA P16234 1/20 0.55
FLT3 P36888 1/20 0.55
TYRO3 Q06418 1/20 0.55
DDR1 Q08345 1/20 0.55
MERTK Q12866 1/20 0.55
AURKB Q96GD4 1/20 0.55
ALK Q9UM73 1/20 0.55
INSR P06213 1/20 0.41
TTK P33981 1/20 0.35
NTRK1 P04629 1/20 0.34
NTRK2 Q16620 1/20 0.34
CDK4 P11802 4/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1639473 0.95 AXL (0.66) AXLKDREGFRAURKARET
SCHEMBL467621 0.94 AXL (0.63) AXLKDREGFRAURKARET
SCHEMBL467767 0.91 AXL (0.67) AXLKDREGFRAURKARET
SCHEMBL30090932 0.91 AXL (0.67) AXLKDREGFRAURKARET
SCHEMBL467787 0.90 AXL (0.65) AXLKDREGFRAURKARET
SCHEMBL30090812 0.90 AXL (0.65) AXLKDREGFRAURKARET
SCHEMBL30090823 0.90 AXL (0.58) AXLKDREGFRAURKARET
SCHEMBL1640351 0.90 AXL (0.58) AXLKDREGFRAURKARET
SCHEMBL1640253 0.90 AXL (0.69) AXLKDREGFRAURKARET
SCHEMBL467783 0.88 AXL (0.59) AXLKDREGFRAURKARET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2387395-A1 AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER Rigel Pharmaceuticals, Inc. (US) 2011-11-23 EP disclosed
US-8040491-B2 Exposure method, substrate stage, exposure apparatus, and device manufacturing method NIKON CORPORATION (JP) 2011-10-18 US disclosed
WO-2010083465-A1 AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER RIGEL PHARMACEUTICALS, INC. (US) 2010-07-22 WO disclosed